Navigation Links
Advantagene Announces SPA Agreement With FDA to Launch Phase 3 Trial for Novel Vaccine Aimed at Preventing Prostate Cancer Recurrence
Date:5/19/2011

ffect against the patient's specific tumor, in essence activating the patient's own immune system to prevent tumor recurrence.

Historically, development of therapies for newly diagnosed prostate cancer has been hindered by the very slow progression of this disease. "Based on our previous data, we were able to design a novel clinical approach that allows efficacy assessment at 24-36 months," stated Dr. Aguilar-Cordova.

Protocol development was co-chaired by Drs. Theodore DeWeese, Chair of Radiation Oncology at Johns Hopkins, and Peter Scardino, Chief of Surgery and Chair of Urology at Memorial Sloan Kettering Cancer Center. "We are delighted to lead this study. I participated in early trials with this product, and am enthusiastic that this randomized trial will definitively evaluate its potential," stated Dr. Scardino. If successful, this could be a major advance for patients and the development of new therapies for prostate cancer.

Contacts for further information:

For more information about ProstAtak™ and Advantagene, please visit the Company's website at http://www.Advantagene.com

Company Inquiries:

Brian Guzik
bguzik@advantagene.com
617-916-5445

Partnering Inquiries:

Jefferson Davis
Extera Partners
jdavis@exterapartners.com
617-225-7700 x245

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE Advantagene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vermillion Announces the Appointment of Bruce Huebner to its Board of Directors
2. Ontario Institute for Cancer Research Announces Spin Off Companies Developing Promising Anticancer Technologies
3. ShangPharma Announces First Quarter 2011 Results
4. BioSpecifics Technologies Corp. Announces Data Presentations at Upcoming XVI Annual Federation of the European Societies for Surgery of the Hand Meeting
5. Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
6. Pfenex Inc., Through Its Reagent Proteins Business Division, Announces Submission of Biologics Master File for Recombinant CRM197 to US FDA
7. ACT Announces Oregon Health & Science University as Clinical Trial Site for its Phase 1/2 Clinical Trial Using hESC-Derived RPE Cells for Macular Degeneration
8. InterMune Announces Presentation of Positive Pirfenidone Data at the International Conference of the American Thoracic Society (ATS)
9. Spherix Announces First Quarter Financial Results
10. Stem Cell Assurance Announces the Filing of Its Form 10 Registration Statement
11. 3SBio Inc. Announces Unaudited First Quarter 2011 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... April 16, 2015 OncoTAb, ... Charlotte (UNC Charlotte) spin-out company, announced today the ... Ph.D., M.D., as Chief Operating Officer (COO). Cooper ... experience in developing clinical diagnostic and biotechnology platforms ... disease. , Cooper’s extensive career transcends the field ...
(Date:4/16/2015)... - Bioenterprise Corporation is pleased to announce that it will ... , PEI.  Bioenterprise has established a 3-year strategic ... the commercialization of agricultural technologies and innovations. ... They have been at the heart of agri-innovation in ... Dave Smardon , President & CEO of Bioenterprise Corporation.  ...
(Date:4/16/2015)... SAN DIEGO , April 16, 2015 ... company dedicated to improving cancer surgeries, announced today that ... lead fluorescent cancer illuminator, AVB-620, in women with primary, ... trial, the company also welcomed the addition of ... affairs. The open label, dose escalation study ...
(Date:4/16/2015)... BETHESDA, Md. , April 16, 2015 /PRNewswire/ ... Bio"), a biotechnology company developing non-toxic DCVax® personalized ... has been included in the Loncar Cancer Immunotherapy ... help investors better track the immunotherapy field within ... founders have selected "the top 25 companies" in ...
Breaking Biology Technology:OncoTAb Names Dr. David L. Cooper as COO 2Bioenterprise Corporation Expands into the Maritimes 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 2NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 3
... 5 Experts from PAREXEL International Corporation (Nasdaq: ... services provider, will address important industry issues at ... being held from March 23 - 25, 2009 ... leaders will present on topics ranging from global ...
... BEACH, California and AMSTERDAM, March 5 ,Agendia, a ... the,appointment of Dr. Albert A. (Al) Luderer to ... Dr. Luderer has more than 30 years of ... therapeutic development. Currently, he,is the Chief Executive Officer ...
... WALTHAM, Mass., March 5 Proteon Therapeutics, Inc., announced ... Series B equity financing, led by MPM Capital on ... L.P. This announcement follows the initiation of a ... PRT-201, in patients with end stage renal disease undergoing ...
Cached Biology Technology:PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting 2PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting 3PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting 4PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting 5Agendia Appoints Seasoned Diagnostics Executive Albert A. Luderer to Supervisory Board 2Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company 2
(Date:3/30/2015)... DUBLIN , Mar. 26, 2015 Research and ... addition of the "Global Gesture Recognition Market in ... The analysts forecast the Global Gesture Recognition market ... 12.8% over the period 2013-2018. Gesture recognition ... respond to different gestures of an individual. Gesture recognition ...
(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/4stcg3/india_sensors ) ... Sensors Market Forecast and Opportunities 2020" report ... is projected to grow at a CAGR over ... industrial and healthcare sectors are the key application ... adoption of MEMS technology in sensors is growing ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... Lugano, Switzerland, 14 September 2012 -- Ahead of the ... be released during the ESMO 2012 Congress, over 1,600 ... 2012 at 9:00 (CEST) to anticipate the flavor of ... emerging strategies set to combat cancer, signposting future directions ...
... have developed a method that for the first time ... proteins and subsequently remove them in a repeatable cycle., ... this week in the journal Nature Methods , ... naturally formed proteins in order to create better antibiotics, ...
... ,Boston (Sept. 14, 2012) Eye injuries in ... as weapons, tactics, technology and strategies have evolved. ... cause extensive damage areas not protected by body armor. ... Institute, Massachusetts Eye and Ear will convene in Boston, ...
Cached Biology News:Noteworthy studies at the ESMO 2012 Congress 2Noteworthy studies at the ESMO 2012 Congress 3Noteworthy studies at the ESMO 2012 Congress 4Noteworthy studies at the ESMO 2012 Congress 5Noteworthy studies at the ESMO 2012 Congress 6Noteworthy studies at the ESMO 2012 Congress 7Chemists develop reversible method of tagging proteins 2Chemists develop reversible method of tagging proteins 3
... depletion cocktail is tailored to ... from suspensions of non-human primate ... separated using the StemSep (or ... selection system, achieving a 2.6 ...
... is tailored to highly enrich ... of non-human primate (Rhesus monkey) ... the StemSep compatible 0.5 Tesla) ... CD4+ T cell content of ...
Mol wt: monoisotopic mol wt1,045.5423 Da by calculation...
...
Biology Products: